Concepts for the Construction of a New National Drug Service System

Jian Wang, Chunping Yuan, Hao Wang, Zhirong Zhang, Qiang Zhang, Guiliang Chen, Changxiao Liu, Huimin Hou, Shengli Yang

Strategic Study of CAE ›› 2017, Vol. 19 ›› Issue (2) : 62-67.

PDF(272 KB)
PDF(272 KB)
Strategic Study of CAE ›› 2017, Vol. 19 ›› Issue (2) : 62-67. DOI: 10.15302/J-SSCAE-2017.02.010
Study on Special Subjects

Concepts for the Construction of a New National Drug Service System

Author information +
History +

Abstract

Although the current drug service system can meet the fundamental needs of healthcare in China, outstanding issues exist in all service sectors, including research and development, manufacturing, marketing, and clinical use. Through a literature search, data queries, specialist consultation, and a panel discussion, this study investigated the current status of the drug service system and identified the main problems. We propose an idea for constructing a new national drug service system to provide drugs to the Chinese people that are of high quality, have a reliable therapeutic effect, come at a reasonable price, and exhibit good medical compliance, thus ensuring the efficacy, safety, availability, and reasonability of drugs for clinical use, as well as promoting a structural transformation of the pharmaceutical industry that will enable China to finally transition from a big country into a great power in the global pharmaceutical industry.

Keywords

drug / service system / pharmaceutical industry / supervision / development strategy

Cite this article

Download citation ▾
Jian Wang, Chunping Yuan, Hao Wang, Zhirong Zhang, Qiang Zhang, Guiliang Chen, Changxiao Liu, Huimin Hou, Shengli Yang. Concepts for the Construction of a New National Drug Service System. Strategic Study of CAE, 2017, 19(2): 62‒67 https://doi.org/10.15302/J-SSCAE-2017.02.010

References

[1]
樊代明. 加减乘除话医改 [J]. 医学争鸣, 2016, 7(3): 1–20.
[2]
中华人民共和国工业和信息化部, 国家发展和改革委员会, 科学技术部, 等. 关于印发《医药工业发展规划指南》的通知 [EB/OL]. (2016-10-16) [2016-11-07].
[3]
杨美成, 王林波, 林梅, 等. 国产及进口药品质量差异现状分析及风险控制的研究 [J]. 上海食品药品监管情报研究, 2011, 12(6): 33–45.
[4]
中华人民共和国国家食品药品监督管理局药品注册司. 《仿制药质量一致性评价工作方案(征求意见稿)》起草说明 [EB/OL]. (2012-11-22) [2016-11-15].
[5]
王晓玲, 郭春彦. 儿童用药剂型与规格的国外现状分析 [J]. 中国药学杂志, 2013, 48(17): 1317–1320.
[6]
陈倩, 杜光. 儿科药物剂型现状及管理策略 [J]. 儿科药学杂志, 2013, 19(8): 49–52.
[7]
Delgado-Charro M B, Guy R H. Effective use of transdermal drug delivery in children [J]. Advanced Drug Delivery Reviews, 2014 (73): 63–82.
[8]
匡李聪, 冯国忠. 我国制药产业发展现状分析 [J]. 现代商贸工业, 2015 (10): 7–9.
AI Summary AI Mindmap
PDF(272 KB)

Accesses

Citations

Detail

Sections
Recommended

/